Today CERo announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug Application (IND) for Phase 1 clinical trials of its lead compound, CER-1236, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback